Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 9/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | ROS1 | P08922 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21460565 | 1.00 | HPGD (0.50) | HPGDALDH1A1HSD17B10ALOX15SMN1; SMN2 | |
| SCHEMBL21478068 | 1.00 | HPGD (0.50) | HPGDALDH1A1HSD17B10ALOX15SMN1; SMN2 | |
| SCHEMBL16445963 | 0.88 | TNK2 (0.58) | HPGDALDH1A1HSD17B10ALOX15SMN1; SMN2 | |
| SCHEMBL16446197 | 0.88 | TNK2 (0.58) | HPGDALDH1A1HSD17B10ALOX15SMN1; SMN2 | |
| SCHEMBL16445965 | 0.88 | TNK2 (0.58) | HPGDALDH1A1HSD17B10ALOX15SMN1; SMN2 | |
| SCHEMBL16446172 | 0.85 | KMT2A (0.53) | HPGDALDH1A1HSD17B10ALOX15SMN1; SMN2 | |
| SCHEMBL16453389 | 0.85 | TNK2 (0.60) | HPGDALDH1A1HSD17B10ALOX15SMN1; SMN2 | |
| SCHEMBL18488972 | 0.84 | TNK2 (0.54) | HPGDALDH1A1HSD17B10SMN1; SMN2TNK2 | |
| SCHEMBL23620371 | 0.81 | HCAR3 (0.53) | HPGDALDH1A1HSD17B10ALOX15SMN1; SMN2 | |
| SCHEMBL23620370 | 0.81 | ALDH1A1 (0.58) | HPGDALDH1A1HSD17B10ALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683282-B2 | Multi-substituted pyrimidine derivatives with excellent kinase inhibitory activities | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-06-16 | — | — | US | disclosed |
| US-10683282-B2 | Multi-substituted pyrimidine derivatives with excellent kinase inhibitory activities | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-06-16 | — | — | US | disclosed |
| WO-2019198940-A1 | EXCELLENT KINASE INHIBITORY ACTIVITY-EXHIBITING PYRIMIDINE DERIVATIVE HAVING VARIOUS SUBSTITUENTS | 한국과학기술연구원 | 2019-10-17 | — | — | WO | disclosed |
| US-20190315726-A1 | MULTI-SUBSTITUTED PYRIMIDINE DERIVATIVES WITH EXCELLENT KINASE INHIBITORY ACTIVITIES | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2019-10-17 | — | — | US | disclosed |
| US-20190315726-A1 | MULTI-SUBSTITUTED PYRIMIDINE DERIVATIVES WITH EXCELLENT KINASE INHIBITORY ACTIVITIES | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2019-10-17 | — | — | US | disclosed |
| US-10017478-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017478-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180155297-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180155297-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9850216-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850216-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160176826-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| US-20160176826-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| EP-3030241-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015021149-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-02-12 | — | — | WO | disclosed |
| WO-2015021149-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-02-12 | — | — | WO | disclosed |
| WO-2003040141-A1 | OXAZOLYL-PHENYL-2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683282-B2 | Multi-substituted pyrimidine derivatives with excellent kinase inhibitory activities | JAK1, NUAK1, JAK2 | HPGD 3649/4885ALDH1A1 4059/4885HSD17B10 3446/4885 |
| US-20160176826-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNK2 | HPGD 2051/4885ALDH1A1 3704/4885HSD17B10 1899/4885 |
| US-10017478-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | TNK1, TNNI3K, TNK2 | HPGD 2051/4885ALDH1A1 3704/4885HSD17B10 1899/4885 |
| US-20180155297-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNK2 | HPGD 2051/4885ALDH1A1 3704/4885HSD17B10 1899/4885 |
| US-20190315726-A1 | MULTI-SUBSTITUTED PYRIMIDINE DERIVATIVES WITH EXCELLENT KINASE INHIBITORY ACTIVITIES | JAK1, NUAK1, JAK2 | HPGD 3649/4885ALDH1A1 4059/4885HSD17B10 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.